| Dr Barry K Feinstein, MD | |
|
5924 Harbour Park Dr, Midlothian, VA 23112-2163 | |
| (804) 739-9005 | |
| (804) 739-9006 |
| Full Name | Dr Barry K Feinstein |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 45 Years |
| Location | 5924 Harbour Park Dr, Midlothian, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023095411 | NPI | - | NPPES |
| 726695 | Other | VA | AETNA USHC |
| 029755 | Other | VA | ANTHEM |
| 6000631 | Medicaid | VA | |
| 224952 | Other | VA | MAMSI |
| 59499 | Other | VA | SOUTHERN HEALTH |
| 68372 | Other | VA | SENTERA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | 0101038621 (Virginia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advanced Allergy And Asthma Of Virginia | 3173657566 | 2 |
News Archive
Men's Health Network is pleased to announce the formation of a Men's Health Caucus in official relations with the American Public Health Association. As an active participant of the APHA Annual Meeting for many years we have seen growing interest and excitement generated around the need and desire to form a Men's Health Caucus and we are happy to see it come to fruition.
OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that it has initiated a clinical study in Primary Hyperoxaluria. This announcement bolsters the Company's position as a leader in developing therapies for hyperoxaluria, a debilitating condition that, if untreated, leads to kidney damage and end-stage renal disease.
Most women in developed countries are regularly screened for cervical cancer, but this is often not the case in poorer countries.
Protalix BioTherapeutics, Inc. announced today that the French regulatory authority has granted an Autorisation Temporaire d'Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease. An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists.
› Verified 9 days ago
| Entity Name | Advanced Allergy And Asthma Of Virginia |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104157114 PECOS PAC ID: 3173657566 Enrollment ID: O20100820000716 |
News Archive
Men's Health Network is pleased to announce the formation of a Men's Health Caucus in official relations with the American Public Health Association. As an active participant of the APHA Annual Meeting for many years we have seen growing interest and excitement generated around the need and desire to form a Men's Health Caucus and we are happy to see it come to fruition.
OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that it has initiated a clinical study in Primary Hyperoxaluria. This announcement bolsters the Company's position as a leader in developing therapies for hyperoxaluria, a debilitating condition that, if untreated, leads to kidney damage and end-stage renal disease.
Most women in developed countries are regularly screened for cervical cancer, but this is often not the case in poorer countries.
Protalix BioTherapeutics, Inc. announced today that the French regulatory authority has granted an Autorisation Temporaire d'Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease. An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Barry K Feinstein, MD 5924 Harbour Park Dr, Midlothian, VA 23112-2163 Ph: (804) 739-9005 | Dr Barry K Feinstein, MD 5924 Harbour Park Dr, Midlothian, VA 23112-2163 Ph: (804) 739-9005 |
News Archive
Men's Health Network is pleased to announce the formation of a Men's Health Caucus in official relations with the American Public Health Association. As an active participant of the APHA Annual Meeting for many years we have seen growing interest and excitement generated around the need and desire to form a Men's Health Caucus and we are happy to see it come to fruition.
OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that it has initiated a clinical study in Primary Hyperoxaluria. This announcement bolsters the Company's position as a leader in developing therapies for hyperoxaluria, a debilitating condition that, if untreated, leads to kidney damage and end-stage renal disease.
Most women in developed countries are regularly screened for cervical cancer, but this is often not the case in poorer countries.
Protalix BioTherapeutics, Inc. announced today that the French regulatory authority has granted an Autorisation Temporaire d'Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease. An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists.
› Verified 9 days ago
Joseph R Vilseck, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 13510 Midlothian Tpke, Midlothian, VA 23113 Phone: 804-794-9477 Fax: 804-794-1973 |